Epidermal Growth Factor Receptor-Targeted Therapy of Colorectal Cancer with Panitumumab

Panitumumab is a fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFR), which when overexpressed may contribute to the development and progression of cancer and is present in several solid tumors, including colorectal cancer (CRC). Panitumumab is registered in USA for the treatment of patients with EGFR expressing CRC after disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecancontaining chemotherapy regimens. The present evidence of effectiveness of Panitumumab for the treatment of metastatic CRC is based on objective tumor respose as well as on progression-free survival. This review article summarizes the development of Panitumumab in preclinical and early phase trials in CRC and focuses on the most recent results available from advanced phase clinical trials, with an update on presentations at the 2007 annual meeting of the American Society of Clinical Oncology (ASCO).

[1]  G. Qiao,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2008 .

[2]  W. Scheithauer,et al.  An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  M. Gordon.  Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody Therapies , 2008 .

[4]  M. Moroni,et al.  Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Hecht,et al.  Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: An updated analysis , 2007 .

[6]  J. Berlin,et al.  Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): A pooled analysis of five clinical trials , 2007 .

[7]  B. Neyns,et al.  Patient-reported outcome (PRO)-assessed clinical benefit with panitumumab (Pmab) in metastatic colorectal cancer (mCRC) patients (pts) , 2007 .

[8]  Marc Peeters,et al.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Lee M Ellis,et al.  Targeted therapy trials: approval strategies, target validation, or helping patients? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Berlin,et al.  Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. , 2007, Clinical colorectal cancer.

[11]  M. Saif,et al.  Incidence and management of cutaneous toxicities associated with cetuximab , 2007, Expert opinion on drug safety.

[12]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  B. Neyns,et al.  A phase III randomized controlled trial of panitumumab in patients with metastatic colorectal cancer: subset analyses in elderly patients and in patients with poor performance status. , 2007 .

[14]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[15]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[16]  Z. Hua.  Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer , 2006 .

[17]  R. Goldberg,et al.  Systemic therapy for metastatic colorectal cancer: current options, current evidence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Figlin,et al.  Updated results from a dose and schedule study of Panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies , 2005 .

[19]  J. Berlin,et al.  Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC) , 2005 .

[20]  L. Roskos,et al.  Flexible dosing schedules of panitumumab (ABX-EGF) in cancer patients , 2005 .

[21]  Silvia Benvenuti,et al.  Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.

[22]  J. Meyerhardt,et al.  Systemic therapy for colorectal cancer. , 2005, The New England journal of medicine.

[23]  R. Figlin,et al.  Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. , 2004, International journal of radiation oncology, biology, physics.

[24]  C. Davis,et al.  Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. , 2001, Critical reviews in oncology/hematology.

[25]  C. Davis,et al.  Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. , 1999, Cancer research.